Kyverna Therapeutics, Inc. KYTX Current maturities of long-term debt
Current maturities of long-term debt at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s current maturities of long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s current maturities of long-term debt?
- Kyverna Therapeutics, Inc. (KYTX) reported current maturities of long-term debt of $221K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s current maturities of long-term debt changed year-over-year?
- Kyverna Therapeutics, Inc.'s current maturities of long-term debt decreased by 56.4% year-over-year, from $507K to $221K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s current maturities of long-term debt?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s current maturities of long-term debt has grown at a -43.3% compound annual growth rate (CAGR), from $956K to $307K.